Official title and information are available only for Plus and Premium subscribers.
Patent Pending Amplification or over-expression of the ERBB2 gene occurs in approximately 15-30% of breast cancers.[1][5] It is strongly associated with increased disease recurrence and a poor prognosis.[6] Over-expression is also known to occur in ovarian, stomach, and aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma.
To see the additional information details please login and subscribe to a Plus or Premium account.
